20 Nov 2014
Stem cells have been hailed, and hailed some more, as a breakthrough technology. All the same, they have been slow to make real inroads in the understanding and treatment of Alzheimers disease. That is about to change, according to scientists who spoke at Accelerating the Cure for Alzheimers Disease through Regenerative Medicine. Held November 6 at Duke University, Durham, North Carolina, the symposium was co-chaired by Murali Doraiswamy and Joanne Kurtzberg. Kurtzberg is a pediatrician and cell therapy expert atDuke.
The first clinical trials of stem cells for AD are expected to begin in 2015, speakers said. Some cautioned that many questions remain about how stem cells affect the Alzheimers brain. They debated whether the move into the clinic is premature, noting the need for more research into where in the brain stem cells go and how long they last. On this, attendees were intrigued by some success tracking injected cells with MRI. In addition to therapeutic applications, induced stem cells made from patients with AD and related disorders are helping shed light on disease mechanisms and enabling screens for potentially therapeutic compounds. Research on stem cells remains limited, however, in part because it is largely supported by state initiatives, such as the California Institute for Regenerative Medicine, and private foundations, such as the New York Stem CellFoundation.
Can Stem Cells Treat Alzheimers? Therapies based on stem cells have had some success in other diseases. Transplants of cord blood, for example, are approved by the Food and Drug Administration to treat leukemia and inborn errors of metabolism, Kurtzberg said in a talk in which she described treatments pioneered by the Duke Stem Cell and Regenerative Medicine Program. Clinicians irradiate the patients bone marrow before administering cord blood, then stem cells in the donated blood engraft and replace unhealthy cells. In the last 25 years, more than 35,000 such life-saving transplants have taken place, Kurtzbergnoted.
In Alzheimers disease, however, neurons die off in massive numbers throughout the brain, making cell replacement impractical. This has caused many researchers to overlook stem cell therapy as an option for AD, Mahendra Rao said in his keynote address. Rao leads regenerative medicine at the New York Stem Cell Foundation Research Institute, New York City. Nonetheless, stem cells have demonstrated the ability to improve cognition in animal models. Rather than replacing neurons, they may benefit the brain in other ways, such as by modulating inflammation, stimulating remyelination, and supplying trophic support. This may enhance the life of dying neurons, Rao said. Would injected cells succumb to the surrounding disease, as has been found to happen with fetal neuron grafts in Parkinsons patients (see Apr 2008 news story;Jun 2014 news story)?Quite the opposite, Rao believes. Injected stem cells, which often mature into glia, may help modify the brain environment, thus lowering itstoxicity.
One example of how stem cells can promote neuron health came some time ago from Frank LaFerla of the University of California, Irvine. LaFerla injected mouse neural stem cells into the brains of animals that modeled hippocampal sclerosis and Alzheimers disease. Treated mice improved cognitively but, in synch with what Rao said, injected cells neither became neurons nor lowered A or tau pathology. Instead, they promoted formation of synapses in the CA1 region of the hippocampus, an effect LaFerla traced to stem cells releasing brain-derived neurotrophic factor (BDNF). Knocking down this growth factor in the cells before injecting them abrogated the treatment benefit (see Jul 2009 news story).Could stem cells slow disease progression? When LaFerla modified neural stem cells to express the A-degrading enzyme neprilysin, treatment with these cells lowered A deposits throughout mouse brain (see Aug 2010 conference story).It is not clear if this step improves cognition further, LaFerla said in answer to an audiencequestion.
Stem cells may also replace sick glia. Kurtzberg described the use of cord blood stem cells to treat Krabbes disease in children. This genetic disorder is caused by the lack of the enzyme galactosylceramidase, which helps maintain the myelin wrapped around axons. Babies born with this condition develop muscle weakness and seizures, and most die before they are 2 years old. However, those who receive cord blood transplants around one month of age, before symptoms appear, survive and generally thrive, with only mild development delays, Kurtzberg said (see Escolar et al., 2005).
Most of the stem cells that engraft in the brains of these children become glia. Studying engrafted cells in postmortem samples, Kurtzbergs group found that they shared properties of microglia and oligodendrocytes. In mouse models, these cells secrete soluble anti-inflammatory factors, stimulate neurogenesis, and promote remyelination. The researchers are now generating these cells in vitro and are about to begin a Phase 1 trial to test whether delivering them into cerebrospinal fluid, in addition to the standard cord blood transplant, is safe in children with Krabbes disease. The differentiated cells should engraft more quickly than do stem cells, which take months to provide the full benefit, and thus may improve outcomes, Kurtzbergnoted.
Amyloid deposits (green) in cortex and hippocampus of mice treated with human mesenchymal stem cells (right) are reduced by one-third compared to untreated mice (left). [Image courtesy of Alexei Lukashev and Tristan Bolmont, StemedicaInternational.]
In other cases, it is not yet clear what the stem cells do. Researchers led by Alexei Lukashev of the biotech company Stemedica International, Epalinges, Switzerland, presented a poster on the use of human adult mesenchymal stem cells to combat Alzheimers disease. First author Tristan Bolmont injected the cells into the bloodstream of 15-month-old APP/PS1 miceonce per week for 10 weeks. The amyloid load in the hippocampus of treated mice dropped by one-third compared with untreated controls. Meanwhile, more microglia clustered around plaques, while the number of pro-inflammatory microglia shrank, suggesting that the stem cells somehow influence this balance. In ongoing work, the authors are characterizing this, as well as testing behavior in treated mice. The cells appeared safe, with no increase in vascular amyloid ormicrohemorrhage.
Human mesenchymal stem cells are currently in a Phase 1/2 clinical trialfor stroke. Lukashev said he is applying for FDA approval for a Phase 2 Alzheimers study to start next year. Similar approaches by other groups are in trials for multiple sclerosis and amyotrophic lateral sclerosis (ALS) (see Oct 2010 news story).
Other stem cell-based Alzheimers treatments are also on the threshold of the clinic. Ellen Feigal, who leads research and development at the California Institute for Regenerative Medicine (CIRM),noted that her organization has given out 17 awards for Alzheimers projects; three of those are now applying for FDA approval for trials. Two academic studies identified small neuroprotective molecules through screens of stem cells; the third, led by Alexandra Capela at the biotech company StemCells Inc., Newark, California, proposes to transplant neural stem cells into AD patients (see CIRM award).
Conference attendees disagree whether the technology is ready for human study. We are rushing too fast to the clinic, LaFerla cautioned, noting that many questions of basic science remain
ed to be answered. Also, researchers do not yet know how many cells to deliver, where, and how often in order to optimize the response, he said. Bolmont conceded that questions remain, but said he felt many of them can be answeredonlyby trials. We could do two more years of mouse studies, and we would still have the same question about whether these treatments will work in humans, he told Alzforum. Feigal urged that trials and research run in parallel. We dont need to paralyze trials while answering basic questions. Clinical trials can inform research. It is a two-way street, shesaid.
Thomas Finn from the FDA spelled out potential safety concerns for which his agency will watch. They include whether intravenous injections of stem cells might block capillaries, causing embolisms and damaging brain tissue. Another question is whether stem cells might give rise to tumors, or make the wrong kind of cells or connections in the brain, leading to side effects like chronicpain.
Stem cells labeled with the MRI agent SPIO spread through one brain hemisphere after injection into a carotid artery. [Image courtesy of Piotr Walczak, Miroslaw Janowski, Jeff W.M. Bulte, etal.]
Tracking Cells in Vivo To allay these concerns, researchers want to be able to follow injected stem cells to see where they go and what kind of cells they become. In his talk, Jeff Bulte, a radiologist at Johns Hopkins University, Baltimore, discussed ways to label stem cells with contrast agents so that MRI can tracked them (see Ahrens and Bulte, 2013). One such agent, superparamagnetic iron oxide (SPIO), is sensitive and appears safe, having been used in several clinical trials. In a human case study, SPIO maintained a signal for more than four months (see Janowski et al., 2014). However, this compound has been pulled from the market for economic reasons, Bulte toldAlzforum.
Probes containing the stable isotope fluorine-19 (19F) emit a bright signal but are less sensitive than SPIO (see Ruiz-Cabello et al., 2008). Celsense Inc. of Pittsburgh markets these probes, which are in use in at least one clinical trial. Bultes own company, SenCEST LLC, Fulton, Maryland, develops chemical exchange saturation transfer (CEST) agents. Instead of using metal, the exchange of a proton between the agent and surrounding water creates the signal. All three approaches demonstrate potential for human use at this time, Bultesaid.
With all these labels, however, the signal fades over time. Bulte is experimenting with reporter genes that could give long-term information on injected cells, with the added advantage of turning off when cells die. As an example, he said that stem cells can be engineered to express a thymidine kinase from herpes simplex virus, which is then detected by a thymidine analogue probe using CEST (see Bar-Shir et al., 2013;Bar-Shir et al., 2013). Bulte also found that stem cells can be targeted to areas of inflammation by making them express the docking protein VLA-4 on their cell surface. This molecule binds to VCAM-1, which is expressed by inflamed endothelial cells. This way, stem cells penetrate into the brain three- to fourfold better, Bulte claimed (see Gorelik et al., 2012).
Such tracking technologies provide a glimpse into the life of injected cells. Using MRI labels, Bulte found that stem cells injected into carotid arteries fanned out across the brain more broadly than cells injected into the brains ventricles or parenchyma (see image above). In an animal study, injection of large cells by this route did not disrupt the integrity of blood vessels in the brain, Bultesaid.
Modeling Disease: What if Craig Had an Alzheimer Mutation? Short of treating disease, researchers hope that stem cells will at least model human disease more faithfully than do animals or cell lines. Lawrence Goldstein of the University of California, San Diego, previously reported that induced neurons generated from people with APP mutations produced loads of A40 and phosphorylated tau (see Jan 2012 news story).At Duke, Goldstein noted that genetic variability between individual people poses a problem for modeling disease with induced pluripotent stem (iPS) cells. To address this, he generated iPS cells from a person whose genome was fully sequenced: genetics pioneer Craig Venter (see Nov 2008 news story).Then he introduced mutations in either APP or presenilin and compared the results. To his surprise, presenilin mutations did not boost phosphorylated tau, while APP mutations did. Why this difference? Goldstein does not know yet. Currently, he is culturing induced Venter neurons with astrocytes to see if cellular interactions might influence tauprocessing.
Neurons in iPS cells can model other neurodegenerative diseases as well. Chris Henderson of Columbia University, New York City, generated induced corticospinal motor neurons, which selectively degenerate in ALS. Henderson compared their gene expression profile to that of oculomotor neurons, which remain intact throughout the disease, to learn what makes spinal motoneurons so vulnerable. He turned up 15 candidate susceptibility genes and four potential resistance genes. When he knocked out one of the susceptibility genes, matrix metalloproteinase-9 (MMP-9), from ALS mouse models, they lived 80 days longer than littermate controls, extending their lifespan by about one-quarter. MMP-9 is expressed almost exclusively by motor neurons and might make an attractive therapeutic target, Henderson suggested (see Kaplan et al., 2014).
Researchers also use induced neurons to screen drugs. Goldstein screened a library of 3,000 compounds on induced neurons from AD patients. He found four classes of drug that lowered A, and said he is working on advancing some of them to the clinic. Henderson screened 50,000 compounds on induced motor neurons to find some that stimulated axon growth in an inhibitory environment. Surprisingly, statins boosted axon extension the most, leading to a 30-fold increase in growth. Henderson believes that the drugs are acting via a mechanism other than cholesterol. Statins themselves would not make good ALS therapeutics because they barely enter the brain and have systemic side effects, he noted. He is looking for other ways to stimulate the samepathway.
Attendees debated whether stem cells will lead to personalized medicine. In theory, clinicians could use iPS cells to generate replacement cells that contain a patients own DNA. By studying iPS cells from multiple donors, researchers could find specific genetic factors that predict whether a given patient will respond to a particular therapy. Clinicians want these options, speakers said, but pharmaceutical companies protest that such approaches would not be commercially viable. In practice, stem cell therapies will not attempt genetic matching in the foreseeable future, clinicians agreed. The question of whether autologous injected stem cells will last for a lifetime without inflaming the immune system will likely be answered sooner.Madolyn BowmanRogers
No Available Comments
To make a comment you must login or register.
Link:
Ready or Not: Stem Cell Therapies Poised to Enter Trials ...
- Stem Cells In Human Trials - September 15th, 2011 [September 15th, 2011]
- NZ Stemcell Trials - Part One - September 15th, 2011 [September 15th, 2011]
- CIRM Major Facilities Speed Stem Cell Science and Create Jobs - September 15th, 2011 [September 15th, 2011]
- Geron's Embryonic Stem Cell Clinical Trial for Spinal Cord Injury - September 15th, 2011 [September 15th, 2011]
- Hans Keirstead - Stem Cell Research Human Clinical Trials - September 15th, 2011 [September 15th, 2011]
- Stem-Cell Human Trials - September 15th, 2011 [September 15th, 2011]
- Geron: FDA Clearance for Human Clinical Stem Cell Trials - September 15th, 2011 [September 15th, 2011]
- Eric Legrand Rutgers University shout out, Listen up! - September 20th, 2011 [September 20th, 2011]
- How to Mend a Broken Heart - September 20th, 2011 [September 20th, 2011]
- Human Embryonic Stem Cell History! - September 20th, 2011 [September 20th, 2011]
- Robert Lanza - ACT - Stem cells and organ cloning interview - September 20th, 2011 [September 20th, 2011]
- Toonari Post Health News: Europe's first clinical trial using human embryonic stem cells - September 23rd, 2011 [September 23rd, 2011]
- Diabetes: Spotlight on Stem Cell Research - Ed Baetge - September 23rd, 2011 [September 23rd, 2011]
- Talking Apes being created by Science | Planet of the Apes, here we come! - September 24th, 2011 [September 24th, 2011]
- Health news: Internet use, sleep, human stem cell research - September 24th, 2011 [September 24th, 2011]
- Geron - September 24th, 2011 [September 24th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - A Father's Story - September 24th, 2011 [September 24th, 2011]
- The Frankenstein Syndrome Trailer - September 24th, 2011 [September 24th, 2011]
- Leukemia: Spotlight on Stem Cell Research - Patient Stories - September 24th, 2011 [September 24th, 2011]
- Geron Corp. Initiates First Human Study Of Embryonic Stem-Cell Therapy - September 24th, 2011 [September 24th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Yung-Wei Chi - September 24th, 2011 [September 24th, 2011]
- Stemcells come alive: Fix Mouse with severed spine ABCnews - September 24th, 2011 [September 24th, 2011]
- StemCells Gains 5% on Neural Stem Cell Trial in Spinal Cord Injury - September 24th, 2011 [September 24th, 2011]
- Stem-Cell Research on Animals - September 24th, 2011 [September 24th, 2011]
- First hESC Therapy Clinical Trial - September 24th, 2011 [September 24th, 2011]
- Stem Cell Testing on Human Subjects [Officially] Begins • NBC Nightly News • October 11th, 2010 - September 24th, 2011 [September 24th, 2011]
- Leukemia: Spotlight on Stem Cell Research - Catriona Jamieson - September 24th, 2011 [September 24th, 2011]
- First stem cell trial begins - September 24th, 2011 [September 24th, 2011]
- Parkinson's Disease: Spotlight on Stem Cell Research - Arnold Kriegstein - September 24th, 2011 [September 24th, 2011]
- Becoming a Blood Stem Cell Donor - September 24th, 2011 [September 24th, 2011]
- Stem cells might be able to reverse the effects of a heart attack. - September 24th, 2011 [September 24th, 2011]
- Horse Stem Cell Video.mp4 - September 25th, 2011 [September 25th, 2011]
- Stem cell trials to begin - September 25th, 2011 [September 25th, 2011]
- Lou Gehrig's Disease (ALS): Progress and Promise in Stem Cell Research - September 25th, 2011 [September 25th, 2011]
- Hans Keirstead - September 25th, 2011 [September 25th, 2011]
- Stem Cell Quiz - September 25th, 2011 [September 25th, 2011]
- NZ Stemcell Trials - Part Two - September 25th, 2011 [September 25th, 2011]
- Drug Trials in a Dish - September 25th, 2011 [September 25th, 2011]
- Rise and Walk - September 25th, 2011 [September 25th, 2011]
- Catriona Jamieson: Therapies Based on Cancer Stem Cells - September 27th, 2011 [September 27th, 2011]
- Vatican lending hand in adult stem cell research - September 28th, 2011 [September 28th, 2011]
- Why STEM-Enhance? - September 28th, 2011 [September 28th, 2011]
- Genetic Underpinnings of Alopecia Areata - September 29th, 2011 [September 29th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Ann Tsukamoto - September 29th, 2011 [September 29th, 2011]
- stem cell trial for leading causes of blindness - October 9th, 2011 [October 9th, 2011]
- Forbes Discusses Stem Cell Research - Video - October 13th, 2011 [October 13th, 2011]
- Bruce Conklin: Drug screening with stem cells - Video - October 13th, 2011 [October 13th, 2011]
- Human Trials of Embryonic Stem Cell Treatment Beginning - Video - October 13th, 2011 [October 13th, 2011]
- Rise and Walk - Video - October 13th, 2011 [October 13th, 2011]
- Mesenchymal Stem Cell Trials - Video - October 14th, 2011 [October 14th, 2011]
- Spinal Cord Injury: Progress and Promise in Stem Cell Research - Video - October 14th, 2011 [October 14th, 2011]
- Better Drugs Through Stem Cells - Video - October 16th, 2011 [October 16th, 2011]
- Adult Stem Cells Used To Rebuild Heart Tissue / Video - Video - October 16th, 2011 [October 16th, 2011]
- GARY RABIN- ADVANCED CELL TECHNOLOGIES 2011 - Video - October 21st, 2011 [October 21st, 2011]
- Stem cell treatment on horse a success, vet says - Video - October 21st, 2011 [October 21st, 2011]
- MAJOR EMBRYONIC STEM CELL BREAKTHROUGHS - Video - October 22nd, 2011 [October 22nd, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Stephen Huhn - Video - November 13th, 2011 [November 13th, 2011]
- Human Cloning has Begun | Playing God? - Video - November 15th, 2011 [November 15th, 2011]
- Diabetes: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video - November 15th, 2011 [November 15th, 2011]
- Brain Tumors: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video - November 15th, 2011 [November 15th, 2011]
- Double Blind Trial of Stem Cells for Heart Failure - Video - December 4th, 2011 [December 4th, 2011]
- Cardiac Stem Cell Therapy Clinical Trial - Video - December 4th, 2011 [December 4th, 2011]
- Glasgow Hospital Conducts First Stem Cell Trials on Stroke Patients - Video - December 4th, 2011 [December 4th, 2011]
- Dr Dietrich discusses the Geron stem cell trial to treat acute spinal cord injury - Video - December 4th, 2011 [December 4th, 2011]
- Stem Cell Research Today: Larry Goldstein - CIRM Science Writer's Seminar - Video - December 7th, 2011 [December 7th, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video - December 22nd, 2011 [December 22nd, 2011]
- Clinical trials and stem cells: what patients should consider - Video - January 2nd, 2012 [January 2nd, 2012]
- Spare Parts for Humans: Tissue Engineers Aim for Lab-Grown Limbs, Lungs and More - Video - January 4th, 2012 [January 4th, 2012]
- CIRM Grant Writing: RFA's - Where does your Project Fit? - Video - January 5th, 2012 [January 5th, 2012]
- Prometheus and I: building new body parts from stem cells (15 Nov 2011) - Video - January 5th, 2012 [January 5th, 2012]
- News Bulletin 18 November 2011 -- The Christian Institute - Video - January 5th, 2012 [January 5th, 2012]
- The Brain on Trial: How Neuroscience Challenges the Law as We Know It - Video - January 5th, 2012 [January 5th, 2012]
- The Human Genome and Individualized Medicine - David Valle, MD - Video - January 5th, 2012 [January 5th, 2012]
- 2010 Professional of Distinction - Discovery Awards - Video - January 23rd, 2012 [January 23rd, 2012]
- Research at The Nebraska Medical Center Biologics Production Facility - Video - January 24th, 2012 [January 24th, 2012]
- ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived ... - January 30th, 2012 [January 30th, 2012]
- StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision - January 31st, 2012 [January 31st, 2012]
- $30 million donation from Boris family will help McMaster turn stem cell research into therapy - February 6th, 2012 [February 6th, 2012]
- Stem Cell Treatment For Blindness Shows Promise In Trials - February 7th, 2012 [February 7th, 2012]
- ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from ... - February 13th, 2012 [February 13th, 2012]